Use of glutamyl-cysteinyl-glycine disodium in the treatment of tuberculosis in children

The aim was to assess the efficacy and tolerability of treatment of respiratory tuberculosis with the inclusion of glutamyl-cysteinyl-glycine sodium (Glutoxim) as part of pathogenetic therapy in children and adolescents. Materials and methods . In retrospective non-comparative study, we studied the the medical records of 33 children and adolescents (aged 8-18 yrs, average age 14.8 yrs) who received complex antituberculosis treatment including of Glutoxim in the inpatient department of the Children’s branch of the Moscow Research and Clinical Center of TB control in the period from 2020 to 2023. Results . On the background of complex treatment with inclusion of Glutoxime early clinical and radiological positive dynamics was noted in the form of disappearance of symptoms of intoxication (in 2 months in 48,5%, 95% CI 31,9 - 65,3%), reduction of infiltration and closure of decay cavities (in 33,3% of patients in 2 months), normalisation of laboratory parameters in the development of adverse reactions (leukopenia in 51,5% of children). Conclusion . Treatment of children with Glutoxim contributed to improved patient tolerance of anti-tuberculosis drugs and a more favorable course of the tuberculosis process. The drug can be recommended as a pathogenetic therapy for children with tuberculosis.